Indivior plc Stock
€27.00
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Indivior
sharewise wants to provide you with the best news and tools for Indivior, so we directly link to the best financial data sources.
Financials
News
Supernus Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Supernus Pharmaceuticals, Inc.? Here are five stocks we like better.
- Supernus and Indivior proposed an all-stock, tax-free merger of equals that would create a
Indivior Q2 Earnings Call Highlights
Key Points
- Interested in Indivior PLC? Here are five stocks we like better.
- Indivior and Supernus plan an all-stock merger of equals expected to close in Q4 2026, subject to approvals. The
Why Supernus Pharmaceuticals Stock Topped the Market Today
Supernus Pharmaceuticals (NASDAQ: SUPN) began the stock trading week on a high note, announcing a major merger alongside its latest quarterly earnings release.
Investors ultimately decided to be
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
On June 11, 2026, Christian Heidbreder, Chief Scientific Officer at Indivior Pharmaceuticals (NASDAQ:INDV), reported the sale of 18,586 shares of common stock in an open-market transaction, as
What to Know About This Fund's $74.8 Million Indivior Sale
On May 15, 2026, Divisadero Street Capital Management disclosed it sold 2,263,703 shares of Indivior (NASDAQ:INDV), an estimated $74.76 million trade based on quarterly average pricing.
According to
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%
On May 15, 2026, Madison Avenue Partners disclosed a new position in Indivior (NASDAQ:INDV), acquiring 4,315,162 shares in the first quarter—an estimated $142.51 million trade based on quarterly
Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally
On May 11, 2026, Claret Asset Management Corp disclosed a new position in Indivior (NASDAQ:INDV), acquiring 707,267 shares in a trade estimated at $23.36 million based on quarterly average pricing.